[Significance of amikacin administered orally prior to operation for prevention of postoperative infections in colonic cancer surgery].
Since December of 1983, clinical trial was undertaken on the prophylactic use of amikacin sulfate (AMK) and metronidazole (MET) in colonic cancer surgery. Daily dose of AMK 1,600 mg and MET 1,000 mg was administered orally in 4 divided doses to 17 patients with colonic cancer for 3 days prior to operation. As a result, wound infection was recognized in only one of 17 cases treated (5.9%). An examination was also performed on bacterial flora in the feces. After the administration of AMK and MET, E. coli and Klebsiella were remarkably decreased, however, E. faecalis and Candida remained unchanged. P. aeruginosa and Bacteroides detected in a few cases were also reduced. These bacteria were restored to the pretreatment level in 1 or 2 weeks after operation.
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000583:Amikacin / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003110:Colonic Neoplasms / Q000601:surgery*; D005243:Feces / Q000382:microbiology; D005260:Female; D006801:Humans; D008795:Metronidazole / Q000008:administration & dosage / Q000627:therapeutic use; D011292:Premedication; D011300:Preoperative Care; D013530:Surgical Wound Infection / Q000517:prevention & control*
D008795:Metronidazole; D000583:Amikacin